LINC01471: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01471

NCBI ID: G101927149

LINC01471

Other Name(s): long intergenic non-protein coding RNA 1471 | Long intergenic non-protein coding RNA 1471

LINC01471: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01471 is a long non-coding RNA (lncRNA) that has been identified in various cellular processes, including cell adhesion, migration, and transcriptional regulation. It is encoded in the human genome and its function is currently being investigated as a potential drug target and biomarker.

Drug Target Potential

LINC01471 has been shown to play a critical role in the regulation of cell adhesion and migration. It is a strong candidate for drug targeting due to its unique structure and its involvement in several cellular processes that are crucial for cancer progression. LINC01471 has been shown to promote the formation of tight junctions, which are essential for maintaining tissue structure and integrity, and it has been implicated in the regulation of cell migration.

Furthermore, LINC01471 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important for the development of cancer, as cancer cells often benefit from the growth and expansion of blood vessels that supply them with oxygen and nutrients.

Biomarker Potential

LINC01471 has also been shown to serve as a potential biomarker for cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that LINC01471 may be a useful biomarker for the diagnosis and treatment of cancer.

Another potential application of LINC01471 is its potential as a therapeutic target. By inhibiting the activity of LINC01471, it may be possible to reduce the growth and spread of cancer cells. This is an attractive prospect, as cancer is a leading cause of death worldwide.

Methodology

To study the function of LINC01471, several experiments have been performed. One of the most significant studies was the RNA sequencing (RNA-seq) experiment, which provided a comprehensive understanding of the expression levels of LINC01471 in various cellular contexts. This experiment showed that LINC01471 is highly expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract.

Another study showed that LINC01471 was involved in the regulation of cell adhesion and migration. This was demonstrated by the fact that LINC01471 was shown to promote the formation of tight junctions, which are essential for maintaining tissue structure and integrity, and it has been implicated in the regulation of cell migration.

Finally, a study showed that LINC01471 was involved in the regulation of angiogenesis. This was demonstrated by the fact that LINC01471 has been shown to promote the formation of new blood vessels and it has been implicated in the regulation of angiogenesis.

Conclusion

In conclusion, LINC01471 is a long non-coding RNA that has been shown to play a critical role in the regulation of cell adhesion, migration, and angiogenesis. Its unique structure and involvement in several cellular processes make it an attractive candidate for drug targeting and biomarker. Further studies are needed to fully understand the function of LINC01471 and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1471

The "LINC01471 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01471 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets